Jonathann Kuo, MD




BA: Boston University
MD: Boston University
Residency: New York Presbyterian Hospital / Weill Cornell
Fellowship: New York Presbyterian Hospital / Hospital for Special Surgery / Memorial Sloan Kettering Cancer Center

Founder, CEO, & Medical Director, Pain Medicine

Jonathann Kuo, MD is a double Board-Certified Pain Management Specialist and Anesthesiologist. He is the founder of Hudson Health, an innovative healthcare system with four integrated practices: Hudson Medical for interventional regenerative pain management, Hudson Wellness for preventative wellness, Hudson Mind for interventional mental health, and Hudson Life for functional and longevity medicine.
Since opening Hudson in 2010, Dr. Kuo and his group has treated over 30,000 patients. His dedication to patient care is matched by his steadfast contributions to clinical research. Having collaborated with renowned doctors and health organizations across the globe, Dr. Kuo has emerged as a prominent thought leader across the interventional pain management and orthobiologics fields.
In his spare time, Dr. Kuo is an accomplished artist who has exhibited at several galleries and displays many of his works across Hudson Health’s TriBeCa and West Village practices. He also enjoys biohacking, cycling, travel gastronomy, and spending time with his growing family.
Dr. Kuo graduated from the prestigious 7 year accelerated BA/MD program at Boston University. He then completed his training at the most prestigious hospital in NYC—New York Presbyterian Hospital Cornell/Columbia. He received additional Fellowship training in Pain Management at Memorial Sloan Kettering Hospital and the Hospital for Special Surgery. He is certified in peptide therapies and has completed advanced coursework through SSRP and the American Academy of Anti-Aging Medicine.
Dr. Kuo and his Hudson Health team are “Experts in Pain,” having treated over 50K patients in 15 years. The Hudson team maintains its high standard of care by employing an in-house algorithm called The Hudson Method to treat pain in the most efficient and efficacious way for each and every patient. Over the course of his 15-year career, Dr. Kuo has become a renowned leader in interventional orthopedics, having performed over 30,000 x-ray and ultrasound-guided spinal and joint procedures. His constant drive for innovation and excellence, combined with intellectual and academic curiosity, has also brought him to the forefront of the rapidly advancing anti-aging, regenerative fields and interventional mental health fields.
Hudson Health’s robust Regenerative Medicine practice has performed over 2500 cases to date with proprietary methods of extracting the highest concentrations of biologics using a flexible lab platform. Hudson Medical is also the first practice in the US to publish safety data on the use of exosomes in spinal applications, and

Dr. Kuo is committed to continually spearheading research in this field. Dr. Kuo actively contributes to clinical research that evaluates the newest biologics and their applications in degenerative spinal and joint and systemic inflammatory conditions. He has traveled extensively to leading laboratories to collaborate with global thought leaders in the regenerative field.
Dr. Kuo has co-authored numerous publications on the use of NAD+, Exosomes, and Stellate Ganglion Blocks as potential Long COVID-19 treatments, and the efficacy of Dual Sympathetic Blocks in treating anxiety disorders. He is currently involved in multiple clinical research projects.

More about Dr. Kuo


English, Chinese (Mandarin), Chinese (Cantonese), Taiwanese

Hospital affiliation

North Shore / Long Island Jewish Hospital, Mt. Sinai / Beth Israel Medical Center

Areas of Interest

Dr. Kuo’s research interests include Regenerative Medicine using Bone Marrow Concentrate which contains stem cells, and Platelet-rich plasma (PRP).

Dr. Kuo’s research interests include Regenerative Medicine using Bone Marrow Concentrate which contains stem cells, and Platelet-rich plasma (PRP).


Block T, Kuo J. Rationale for Nicotinamide Adenine Dinucleotide AD+) Metabolome Disruption as a Pathogenic Mechanism of Post-Acute COVID-19 Syndrome. Clin Pathol. 2022;15:2632010X221106986. Published 2022 Jun 24. doi:10.1177/2632010X221106986

Rationale for NAD+ Metabalome Disruption as a Pathogenic Mechanism of Post-Acute COVID 19 Syndrome

One Month Safety Study of ExFlo Injection for the Treatment of Lumbar or Cervical Radiculopathy

Clinical Trials

fMRI evaluation of the effect of Stellate Ganglion Blocks for PTSD, in conjunction with NYU Langone and the Stella Center

Clinical Trial

Therapeutic application of Dual Sympathetic Blocks for Long COVID Management

Clinical Trial

Potential use of Anti-Inflammatory Supplements (Root.Health) for Reducing Pain Biomarkers in Chronic Pain Patients

Clinical Trial

Coming Soon →
Safety of bone marrow derived mesenchymal stem cell extracellular vesicle injection for lumbar facet joint pain

Clinical Study

Thought Leadership

Reimagined healthcare, designed for you.

Book an appointment with a Board-Certified doctor.